Nedosiran sodium |
Katalog-Nr.GC70681 |
Nedosiran sodium ist ein GalNAc-dsRNA-Konjugat zur Hemmung der Produktion des hepatischen Lactatdehydrogenase (LDH)-Enzyms.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2247026-22-6
Sample solution is provided at 25 µL, 10mM.
References:
[1]. Kevin Shee, et al. Nedosiran Dramatically Reduces Serum Oxalate in Dialysis-Dependent Primary Hyperoxaluria 1: A Compassionate Use Case Report. Urology.2021 Oct;156:e147-e149.
[2]. Gema Ariceta, et al. Hepatic Lactate Dehydrogenase A: An RNA Interference Target for the Treatment of All Known Types of Primary Hyperoxaluria. Kidney Int Rep.2021 Feb 3;6(4):1088-1098.
[3]. Thomas A Forbes, et al. Therapeutic RNA interference: A novel approach to the treatment of primary hyperoxaluria. Br J Clin Pharmacol.2021 May 22.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *